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Background: High risk non-ST elevation acute coronary syndrome (HR-NSTE ACS) patients undergoing percutaneous coronary intervention (PCI), 
have a lower risk of bleeding with bivalirudin (BV) compared to unfractionated heparin (UFH) plus a GP IIb/IIIa inhibitor. We implemented a single 
center pilot protocol utilizing upstream BV in the emergency department(ED) for HR-NSTE ACS patients.
Methods: A standardized chest pain protocol was implemented at Ridgeview Medical Center 30 miles away from the PCI center. In addition to 
aspirin and clopidogel, BV was recommended for HR-NSTE ACS (ST depression or positive troponin) prior to transfer for angiography and PCI if 
indicated.
Results: From 4/1/08 to 12/31/10, 1,633 patients were enrolled in a prospective chest pain registry including 178 (11%) STEMI, 256 (16%) 
HR-NSTE ACS, 530 (32%) intermediate risk and 669 (41%) low risk. Despite protocol recommendation, only 32 (12.5%) of the HR-NSTE ACS patients 
received BV as the anticoagulant instead of UFH. Reasons why BV was not used include: (1) inadequate familiarity of BV by ED physicians and non-
interventional cardiologists, (2) cost of BV compared to UFH, (3) delays to angiography and (4) dosing confusion. Outcomes are shown in the table:
NR-NSTE ACS
N=256
Bivalirudin
N=32
Unfractionated Heparin
N=224
P-value
PCI performed 18 (56%) 131 (58%) 0.81
Mortality-30 day 0 14 (6.2%) 0.23
Mortality-1 year 0 29 (13%) 0.032
ReMI/ischemia-30 day 0 1 (0.5%) 1.00
Stroke-30 day 0 0 --
Major bleeding 0 0 --
Conclusions: In contrast to success with STEMI and despite the potential benefit with upstream administration of BV vs. UFH, implementation of a 
protocol in the ED was challenging due to unfamiliarity and cost.
